Releases

Media coverage

Newsletter

Subscribe to our newsletter

Archive


Nov 29, 2016

The Board has decided on a plan to provide financing the ongoing clinical study to develop a cancer medicine based on LTX-315.

The plan entails two steps; a pre-IPO as private placement in Q4/2016 targeting mNOK 60 (with a repair share issue for those of the (small) shareholders who have not been invited to participate in the private placement); as well as an IPO in H2/2017, targeting mNOK 250 – mNOK 450. The IPO will depend on the results of the ongoing phase I study.

An update will be given in  the next Newsletter, planned for January/February 2017.